Our responsible business model
MipSalus is a biotech company with leading-edge expertise in transforming Molecular Imprinted Polymers (MIPs) into a new class of medicines. Currently, MipSalus focuses on developing a breakthrough treatment for the rare and potentially invalidating disease Phenylketonuria, commonly referred to as PKU.
While being deeply engaged in creating a better future for people affected by PKU, MipSalus is also dedicated to building a sustainable business model for our activities.
MipSalus supports UN’s Sustainable Development Goal, in particular:
![E_WEB_03](https://usercontent.one/wp/www.mipsalus.dk/wp-content/uploads/E_WEB_03.png?media=1709219183)
By developing a treatment for PKU, we contribute to the health and well-being of those with inborn errors of metabolism.
![E_PRINT_05](https://usercontent.one/wp/www.mipsalus.dk/wp-content/uploads/E_PRINT_05-scaled.jpg?media=1709219183)
We promote gender equality and to ensure the diversity of our team, we have set specific goals for gender equality which we seek to achieve.
![E_WEB_06](https://usercontent.one/wp/www.mipsalus.dk/wp-content/uploads/E_WEB_06.jpeg?media=1709219183)
We reduce our consumption of water in our production by reclaiming and reusing it.
![E_WEB_12](https://usercontent.one/wp/www.mipsalus.dk/wp-content/uploads/E_WEB_12.png?media=1709219183)
Our production process is built on principles of circular economy with the aim to minimize waste production through reclaiming and reuse.